Business● Low1h ago · Nov 6, 2026, 4:55 AM
Veracyte outlines 2027 view with ~10% volume growth and 22% adjusted EBITDA, while resetting Decipher prostate to 12,000-15,000 incremental tests
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Veracyte has provided its financial outlook for 2027, projecting approximately 10% volume growth and 22% adjusted EBITDA, while adjusting its Decipher prostate test projections. This indicates the company's anticipated future performance and strategic adjustments.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business16m agoDollar to Naira exchange rate today, November 6, 2026Vanguard NigeriaBusiness20m agoIndia as an AI hedge? The country's stocks could see robust inflows as markets globally tankCNBCBusiness22m agoChampBet goes all in on Lagos, pioneering lifestyle betting in NigeriaVanguard NigeriaBusiness33m agoUK tax havens linked to €8bn in EU tax losses: Who loses most?EuroNews [en]